Search Results
Your search for ,OUr matches 10724 pages
Showing 5101 - 5150Oncologist Survey on Knowledge About LGBTQ Patients With Cancer
In a national survey of oncologists reported in the Journal of Clinical Oncology, Schabath et al found that whereas oncologists tended to have limited knowledge regarding lesbian, gay, bisexual, transgender, and queer/questioning (LGBTQ) patient health and cancer needs, they indicated high interest ...
Outcomes With AHCT Consolidation in Younger Patients With Mantle Cell Lymphoma in the Rituximab Era
In a retrospective study reported in the Journal of Clinical Oncology, Gerson et al found evidence that autologous hematopoietic cell transplantation (AHCT) consolidation after induction chemotherapy was associated with a progression-free survival benefit in patients with mantle cell lymphoma aged...
MD Anderson President Emeritus, John Mendelsohn, MD, Dies at Age 82
John Mendelsohn, MD, President Emeritus of The University of Texas MD Anderson Cancer Center, died of glioblastoma on January 7, 2019, at his home in Houston at age 82. He was an internationally acclaimed leader in the field of medicine and scientist whose research helped pioneer a new type of...
Patient Navigation Program Reduces Time to Cancer Treatment
The Global Cancer Institute recently announced the results of its Patient Navigation Program in Mexico City. The average time to referral before the program’s inception was 5 months, but the implementation of patient navigators reduced that average to 7 days. These findings were published by Yanin...
A Tribute to Arti Hurria, MD, FASCO, a Leader in Geriatric Oncology
The oncology community is deeply saddened by the untimely passing of Arti Hurria, MD, FASCO, a nationally regarded expert and advocate for elderly patients with cancer. Dr. Hurria died on November 7, 2018, in a traffic accident. At the time of her tragic death, Dr. Hurria was Director of the City...
Huntsman Cancer Institute Announces Construction of Proton Therapy Center
The Huntsman Cancer Institute (HCI) at the University of Utah recently began construction on a proton therapy center. The $31 million, 7,450 square-foot addition to the HCI’s Cancer Hospital will be the first proton therapy center in the Mountain West. The new center will be named in honor of...
A Visionary in Lymphoma, Bertrand Coiffier, MD, PhD, Dies at 71
Internationally renowned lymphoma expert Bertrand Coiffier, MD, PhD, died on January 2, 2019. He was 71. Dr. Coiffier published more than 500 papers and book chapters that garnered more than 50,000 literature citations, placing him among the top 1% of the most influential researchers globally. His ...
Remnants of Cancer Remain, but Demons Are Now Gone
In the summer of 2002, I was a physically active 17-year-old boy on the cusp of adulthood. I was about to enter my senior year in high school, and like other teens my age, I was excited about college and the promise of the undreamed-of opportunities that lay ahead. At first, the lethargy I was...
Established, Modifiable Cancer Risk Factors
According to a new American Cancer Society report published by Susan M. Gapstur, PhD, MPH, American Cancer Society Senior Vice President of Behavioral and Epidemiology Research, and colleages in CA: A Cancer Journal for Clinicians, the highest priority in a national cancer control plan is the...
FDA Approves Cabozantinib in Previously Treated Hepatocellular Carcinoma
On January 14, the U.S. Food and Drug Administration (FDA) approved cabozantinib (Cabometyx) tablets for patients with hepatocellular carcinoma who have been previously treated with sorafenib. The FDA’s approval of this oral tyrosine kinase inhibitor was based on the results of the phase III...
Findings From ASCO’s Second National Cancer Opinion Survey
Despite a recent study showing that patients with cancer who chose alternative therapies over conventional cancer treatment have a higher risk of death, nearly 4 in 10 Americans believe cancer can be cured by alternative remedies alone, according to the results of ASCO’s 2018 National Cancer...
Clinical Trial Commences on Personalized Vaccine in Kidney Cancer
Researchers at the Dana-Farber Cancer Institute in Boston are testing a first-of-its-kind personalized cancer vaccine combined with an immunotherapy drug, with the aim of improving outcomes for patients with kidney cancer who are at high risk of recurrence after surgery. A two-pronged approach to...
Novel Treatments in Newly Diagnosed Multiple Myeloma, Part 1
Here is an update on several different studies focusing on novel treatments for patients with newly diagnosed multiple myeloma presented at the 2018 American Society of Hematology (ASH) Annual Meeting & Exposition. Featured therapeutics include daratumumab plus lenalidomide and dexamethasone, ...
ASCO to Convene Global Summit on Latest Innovations in Technology and Cancer
Advances in medicine and technology are emerging faster than ever before. To harness this momentum, ASCO is convening Breakthrough: A Global Summit for Oncology Innovators, a new meeting focused on the intersection of medicine, scientific discovery, and innovations in technology. The inaugural...
Improved Data Sharing Through CancerLinQ Certification Continues to Expand
The number of electronic health record (EHR) systems joining with CancerLinQ® to facilitate information sharing continues to grow. CancerLinQ LLC, a wholly owned nonprofit subsidiary of ASCO, announced this past month that Varian’s ARIA Oncology Information System (OIS) is the next Electronic...
Lori J. Pierce, MD, FASTRO, FASCO, Elected ASCO President for 2020–2021 Term
ASCO has elected Lori J. Pierce, MD, FASTRO, FASCO, a long-time member and volunteer, to serve as its President for the term beginning in June 2020. She will take office as President-Elect during the ASCO Annual Meeting in Chicago in June 2019. Six new members were also elected to the ASCO Board of ...
Common Markers of Tumor Hypoxia Found Across Cancer Types
Unlike healthy tissues, tumors thrive in low-oxygen environments, often acquiring the ability to resist treatment and spread to other sites in the body. Despite being a well-known cause of therapy resistance and metastasis, the impact of hypoxia on tumor cells is poorly understood. Researchers have ...
Comorbidities and Cancer Clinical Trial Enrollment
Patients diagnosed with cancer who also have other illnesses or conditions, such as hypertension, asthma, or a prior cancer, are less likely to talk with their health-care provider about a cancer clinical trial, are less likely to be offered to join a clinical trial, and are ultimately less likely...
FDA Approves Cabozantinib for Previously Treated Hepatocellular Carcinoma
On January 14, the U.S. Food and Drug Administration (FDA) approved cabozantinib (Cabometyx) tablets for patients with hepatocellular carcinoma who have been previously treated with sorafenib. The FDA’s approval of cabozantinib was based on results from the phase III CELESTIAL trial....
Al Identifies Features of Tumor Cells in High-Risk Ovarian Cancer
Scientists have developed a new test that scans the shapes of tumor cells to select women with especially aggressive ovarian cancer. A team at The Institute of Cancer Research (ICR), London, created an artificial intelligence (AI) tool that looks for clusters of cells within tumors with misshapen...
Role of Donor Race in Liver Transplant Outcomes in African American Patients With Hepatocellular Carcinoma
Among African American adults undergoing liver transplant to treat hepatocellular carcinoma, patients whose organ donor was also African American lived significantly longer than those with a racially unmatched donor, report authors of a new study using national data. Their findings were published...
Patient Navigation Program Reduces Time to Treatment in Patients With Cancer
Global Cancer Institute recently announced the results of its Patient Navigation Program in Mexico City. The average time to referral before the program’s inception was 5 months, but the implementation of patient navigators reduced that average to 7 days. These findings were published by ...
2018 Young-Onset Colorectal Cancer Survey Report Covers Disease Stage at Diagnosis and More
Nearly three-quarters of patients with young-onset colorectal cancer are diagnosed with an advanced stage of the disease, a significantly higher percentage than has been reported for their more mature peers, according to a report from the Colorectal Cancer Alliance. The findings of...
Quality of Life and Patient- and Clinician-Reported Cumulative Toxicity
New research has found that quality of life for people with cancer is reduced by an accumulation of low-level toxicities just as much as it is from high-level adverse events. Additionally, patient-reported outcomes were more likely to reflect the impact on a patient’s physical well-being than ...
Negative Colonoscopy and Long-Term Risk of Colorectal Cancer
Ten years after a negative colonoscopy, patients who were rescreened for colorectal cancer had a lower risk of being diagnosed with and were less likely to die from colorectal cancer compared with those who did not undergo colorectal cancer screening, according to a study published by Lee et al...
New Study Examines Orphan Drug Exclusivity and Pricing
A new report commissioned by the National Organization for Rare Disorders (NORD) and published by the IQVIA Institute demonstrates that the 7-year market exclusivity granted to drugs designated under the Orphan Drug Act of 1983 for rare diseases is working as intended. In nearly every case, orphan...
ASCO and ESMO Publish Joint Assessment of Their Value Frameworks
TO BETTER UNDERSTAND the performance characteristics of ASCO’s Value Framework Net Health Benefit Score version 2 (ASCO-NHB v2)1 and the European Society for Medical Oncology’s (ESMO’s) Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1),2 ASCO and ESMO undertook a joint project to...
IASLC Announces Dave Mesko, MBA, as New Chief Executive
THE INTERNATIONAL Association for the Study of Lung Cancer (IASLC) has announced Dave Mesko, MBA, as its new Chief Executive Officer. Mr. Mesko replaces Fred R. Hirsch, MD, PhD, who left IASLC after his 5-year term ended on October 31, 2018. Mr. Mesko will be primarily responsible for the overall ...
For Maria Papaleontiou, MD, Research Holds the Key to Improving Care of Patients With Thyroid Cancer
Maria Papaleontiou, MD, whose research interests focus on the complex issues surrounding the management of thyroid cancer and thyroid disease in general, was born on Cyprus, a small island nestled in the azure waters of the Mediterranean Sea. She recently spoke with The ASCO Post about her life and ...
Welcome Questions About Cervical Cancer Treatment Options
TWO STUDIES reported in The New England Journal of Medicine1,2 showed that patients with early-stage cervical cancer had reduced disease-free and overall survival when treated with minimally invasive radical hysterectomy vs open or radical hysterectomy. The findings of these studies have been...
Comparing Survival Outcomes With Minimally Invasive and Open Surgical Approaches to Early-Stage Cervical Cancer
MINIMALLY INVASIVE radical hysterectomy for women with early-stage cervical cancer has been associated with reduced rates of disease-free and overall survival in the phase III LACC randomized noninferiority trial comparing minimally invasive and open abdominal radical hysterectomy. The results...
ASCO Resolutions on Step Therapy, Competitive Acquisition Program Proposed at AMA House of Delegates
During this year’s interim meeting of the American Medical Association (AMA) House of Delegates (HOD), ASCO proposed four resolutions on step therapy, Medicare Part B drugs, a Competitive Acquisition Program, and clinical trial access, all of which were adopted or reaffirmed by the policy-making...
Illustrating Genius
FOUR AND A HALF YEARS AGO, author Neil Canavan attended a scientific conference to learn what he could about the then-emerging field of immunotherapy for cancer. After a presentation by Zelig Eshhar, PhD, principal investigator in the Department of Immunology at the Weizmann Institute of Science...
Global Oncology Education and Professional Development: ASCO International’s Impact
ASCO is such a misnomer: the American Society of Clinical Oncology is far more than simply “American.” Over the past several years, I (a Canadian-born breast surgical oncologist, with an Indian-born mother and a Tanzanian-born father) have traveled to Zimbabwe, Bhutan, and the Philippines with this ...
Improving Palliative Care in Low-Resource Settings
In 2016, ASCO published an update to its Clinical Practice Guideline, “Integration of Palliative Care Into Standard Oncology Care,” which provides evidence-based recommendations for symptom management, clarification of treatment goals, support of coping and distress management, and coordination of...
How to Build a Clinical Trial Infrastructure in the Community Oncology Setting
HISTORICALLY, CLINICAL research has been viewed as an entity belonging to academic settings alone. With the advent of the Community Clinical Oncology Program (CCOP) in the 1980s and later with the Cancer Trials Support Unit, cancer clinical trials have begun to emerge in the community setting....
New Data Reported From International Studies of Lung Cancer Treatment
At the European Society for Medical Oncology (ESMO) 2018 Congress, important studies were presented for every cancer type. Here, The ASCO Post offers some snapshots of lung cancer studies that may inform approaches to treating this common cancer, which—despite the advances in recent years—remains...
Statement From FDA Commissioner on In Vitro Companion Diagnostics
FDA Commissioner Scott Gottlieb, MD, recently issued the following statement on developing and class labeling of in vitro companion diagnostics for classes of oncology therapeutic products: “With a new draft guidance document that the FDA issued … our aim is to make it easier to get class labeling ...
Should I Have Lied?
The ASCO Post is pleased to reproduce installments of the Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
International Trials Present New Findings in Treatment of Breast Cancer
The European Society for Medical Oncology (ESMO) 2018 Congress featured an assortment of study findings, many with far-reaching clinical implications for the treatment of patients with various cancers. Many of these trials were covered in-depth in recent issues of The ASCO Post. Here, we present...
Pembrolizumab Plus Chemoradiotherapy in HPV-Positive Head and Neck Cancer
The addition of pembrolizumab (Keytruda) to a chemoradiotherapy regimen yielded complete response rates of 85% in patients with human papillomavirus (HPV)-positive advanced squamous cell carcinoma of the head and neck. These findings from a phase Ib study were presented at the 2018 Society for...
Overscreening for Prostate Cancer in Older Men Remains an Issue
Although most major cancer organizations agree on the guidelines for prostate cancer screening, there is still uneven application of the test, such as in the older patient population, resulting in overdiagnosis and waste in an already fiscally challenged health-care system. Researchers from the...
Update on Immune Checkpoint Inhibitors
Checkpoint inhibitors have moved the field of immuno-oncology to the forefront of cancer treatment and research. However, these agents come with the risk of serious adverse events. To shed light on the toxicities associated with checkpoint inhibitors and other timely issues in the field of...
The Great Opioid Debate: Treating Cancer Pain Safely
As the number of opioid-related deaths continues to rise in the United States, stakeholders are struggling to make sense of the crisis. At the 2018 Palliative and Supportive Care in Oncology Symposium, two experts in the field, Charles F. von Gunten, MD, PhD, and Leslie J. Blackhall, MD,...
Immunotherapy-Related Toxicities May Be More Common Than Originally Reported
Immunotherapy has significantly improved the overall survival of patients with non–small cell lung cancer (NSCLC) and is generally better tolerated than traditional chemotherapies, but the results of a retrospective study suggested that immunotherapy side effects may be more common than initially...
New NCCN Member Institution: Abramson Cancer Center of the University of Pennsylvania
In November, the National Comprehensive Cancer Network® (NCCN) announced that Abramson Cancer Center (ACC) of the University of Pennsylvania will become the organization’s 28th Member Institution. The Abramson Cancer Center’s membership will include the Hospital of the University of Pennsylvania...
Has Scalp Cooling Reached the Level of Standard of Care?
Does evidence of the effectiveness and safety of scalp cooling to reduce hair loss among women being treated for breast cancer mean that scalp cooling is a new standard of care? “I would suggest that it is,” stated Mikel Ross, MSN, RN, AGNP-BC, of the Breast Medicine Service, Memorial Sloan...
FDA Issues Guidance on Endpoints for Cancer Clinical Trials
This week, the U.S. Food and Drug Administration (FDA) issued a guidance titled Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics. The guidance provides recommendations to applicants on endpoints for cancer clinical trials submitted to the FDA to support effectiveness claims...
Combining a Checkpoint Inhibitor With CAR T-Cell Therapy May Augment Immune Response
Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary approach to treating hematologic malignancies. As experience with this strategy is gained, researchers are learning more about how to optimize responses, especially in patients with “immune exhaustion,” who have a suboptimal initial...
Low-Dose CT Lung Screening: New Developments Support Increased Quality, More Data, Deep Learning
Two years ago, Rick Avila, MS, Chief Executive Officer (CEO) of Accumetra, LLC, was using rolls of Scotch tape as a research tool. The Scotch tape was a phantom, or reference object, and his company was working with computed tomography (CT) lung screening sites around the world to determine the...
